IT major Infosys Ltd on Thursday revised its FY25 revenue guidance to 4.5- 5.0 per cent in constant currency from an earlier 3.75-4.5 per cent. It, however, maintained an operating margin of 20 ...

The company’s utilization stands at 83%, including trainees for Q3 FY25. (Image: Reuters) The attrition rate of Infosys stands at 13.7% for the last twelve months for the IT services for the ...

Revenue from operations, however, showed a solid increase, rising 7.1 per cent YoY to Rs 9,661 crore from Rs 9,017 crore in the year-ago period Mid-tier IT services player LTIMindtree recorded a ...

(RTTNews) - While reporting financial results for the fourth quarter and fiscal 2024 on Thursday, diversified health care company UnitedHealth Group, Inc. (UNH) affirmed its earnings, adjusted ...

today reports a trading update for its first financial quarter of FY25 ending 31 December 2024. SUMMARY • Q1 Group revenues of €1.9 billion with constant currency revenue growth of 3% versus ...

SCHAUMBURG, Ill., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Paylocity Holding Corporation (Nasdaq: PCTY), a leading provider of cloud-based HR, payroll, and spend management software solutions, today ...

Prairie Operating shares rose after the company forecasted that its rate of production would triple in 2025. Shares of the Houston-based oil and natural gas company were recently up 47%, to $7.46 ...

Buoyed by the festive season, an increased number of wedding dates, and signs of improving consumer sentiment, the industry is looking forward to a positive second half of FY25, says a report by ...

“We are working towards becoming Ebitda profitable in FY25, and we’re very certain about it. "What we look forward to in the next financial year is launching new products, stabilising them and ...

As Infosys gears up to announce its third quarter results ending December 31, 2024 (Q3 FY25), all eyes are on the information technology (IT) giant’s performance in a seasonally weak quarter ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178. ...

Sees FY25 gross margin 73%-74%. Sees FY25 adjusted EBITDA margin 25%-26%. “The Company executed extremely well in 2024, delivering high revenue growth across both ...